Search Results for keywords:"Ridgefield New Jersey"

Found 2 results
Skip to main content

Search Results: keywords:"Ridgefield New Jersey"

  • Type:Notice
    Citation:90 FR 17030
    Reading Time:less than a minute

    Sanofi US Services Inc. proposed new production activities at its facility in Ridgefield, New Jersey, and submitted a notification to the Foreign-Trade Zones (FTZ) Board on December 18, 2024. This notification was reviewed according to the Board's regulations, and a public comment invitation was published in the Federal Register on January 6, 2025. By April 17, 2025, the Board decided that no further review was needed, and authorized the activity under the FTZ Act and regulations. The decision was communicated to Sanofi with a formal notice from the Executive Secretary, Elizabeth Whiteman.

    Simple Explanation

    Sanofi, a medicine company, got permission to start making new medicines in New Jersey. Some people had the chance to say what they thought about this idea and nobody said it needed more checking, so it was approved quickly.

  • Type:Notice
    Citation:90 FR 596
    Reading Time:about a minute or two

    Sanofi US Services Inc. has asked the Foreign-Trade Zones Board for permission to start production of pharmaceutical products at its facilities in Ridgefield, New Jersey, within FTZ 49. Specifically, they plan to produce Beyfortus® (Nirsevimab), a vaccine that will be duty-free. The materials needed for this production also include the duty-free Beyfortus® monoclonal antibody active ingredient. The public is invited to comment on this proposal by February 18, 2025, by sending an email to the Board's Executive Secretary.

    Simple Explanation

    Sanofi wants permission to make a special vaccine in New Jersey where they don't have to pay extra taxes, and they are asking people to email their thoughts about this by February 18, 2025.